MSF at the WHO Executive Board 138
EB 138 - Agenda Item 8.5: Global Action Plan on Antimicrobial Resistance | Background information
EB 138 - Agenda Item 9.1: Sharing on diagnostic, preventive and therapeutic products | Background information
EB 138 - Agenda Item 9.2. Draft Global Health sector strategies | Background information
EB 138 - Agenda Item 9.3 - Global Vaccine Action Plan | Background information
EB 138 - Agenda Item 10.3: Follow-up of the report of the CEWG on R&D | Background information
EB 138 - Agenda Item 10.5: Addressing the global shortages of medicines, and the safety and accessibility of children’s medication| Background information
Other background documents
Agenda Item 5 & 8.4 - Briefing - “From Ebola and Beyond: faulty governance of the health system in responding to medical emergencies and epidemics
Agenda Item 8.1 - Briefing - “International Health Regulations: A good framework with weak foundations”
Nearly 1 million children die every year of pneumonia and the vaccine is too expensive for most developing countries.
We need your help. #AskPharma to bring down the price of the pneumonia vaccine so we can vaccinate more kids.
SIGN OUR PETITION
TPP: A BAD DEAL FOR MEDICINE
After 5 years of secret negotiations the US and 11 other Pacific countries have reached an agreement on the full text of the TPP which will now be submitted to national processes for final signature and ratification. Read MSF's reaction.
HANDS OFF OUR MEDS
Join us in urging Indian Prime Minister Modi to protect India’s production of lifesaving affordable generic medicines.
TAKE ACTION NOW!
What is the Campaign?
Médecins Sans Frontières set up the Access Campaign in 1999 to push for access to, and the development of life-saving and life prolonging medicines, diagnostic tests and vaccines for patients in MSF programmes and beyond. We are a multi-disciplinary team that includes doctors, pharmacists, scientists, lawyers, as well as advocacy and communications experts. We also work with patient groups and other civil society organisations in response to their concerns over access to treatment.